2017 |
Aguirre, P; Garcia-Beltran, O; Tapia, V; Munoz, Y; Cassels, B K; Nunez, M Neuroprotective Effect of a New 7,8-Dihydroxycoumarin-Based Fe2+/Cu2+ Chelator in Cell and Animal Models of Parkinson's Disease Artículo de revista Acs Chemical Neuroscience, 8 (1), pp. 178-185, 2017, ISSN: 1948-7193. Resumen | Enlaces | BibTeX | Etiquetas: activity, antioxidant antioxidant, basal brain chelator, complex content, coumarin-based coumarins, disease, ganglia, i, inhibitory-activity, iron iron-copper lipid-peroxidation, model, mouse neurodegeneration neurodegeneration, neuroprotection, niptp oxidative parkinsons stress, with @article{RN346, title = {Neuroprotective Effect of a New 7,8-Dihydroxycoumarin-Based Fe2+/Cu2+ Chelator in Cell and Animal Models of Parkinson's Disease}, author = { P. Aguirre and O. Garcia-Beltran and V. Tapia and Y. Munoz and B.K. Cassels and M. Nunez}, url = {/brokenurl#<Go to ISI>://WOS:000392459400021}, doi = {10.1021/acschemneuro.6b00309}, issn = {1948-7193}, year = {2017}, date = {2017-01-01}, journal = {Acs Chemical Neuroscience}, volume = {8}, number = {1}, pages = {178-185}, abstract = {Disturbed iron homeostasis, often coupled to mitochondrial dysfunction, plays an important role in the progression of common neurodegenerative diseases such as Parkinson's disease (PD). Recent studies have underlined the relevance of iron chelation therapy for the treatment of these diseases. Here we describe the synthesis, chemical, and biological characterization of the multifunctional chelator 7,8-dihydroxy-4-((methylamino)methyl)-2H-chromen-2-one (DHC12). Metal selectivity of DHC12 was Cu2+ similar to Fe2+ > Zn2+ > Fe3+. No binding capacity was detected for Hg2+, co(2+), ca(2+), Mnz+, Mg2+, Ni2+, Pb2+ or Cd2+. DHC12 accessed cells colocalizing with Mitotracker Orange, an indication of mitochondrial targeting. In addition, DHC12 chelated mitochondrial and cytoplasmic labile iron. Upon mitochondrial complex I inhibition, DHC12 protected plasma membrane and mitochondria against lipid peroxidation, as detected by the reduced formation of 4-hydroxynonenal adducts and oxidation of C11-BODIPY581/891. DHC12 also blocked the decrease in mitochondrial membrane potential, detected by tetrarnethylrhodamine distribution. DHC12 inhibited MAO-A and MAO-B activity. Oral administration of DHC12 to mice (0.25 mg/kg body weight) protected substantia nigra pars compacta (SNpc) neurons against MPTP-induced death. Taken together, our results support the concept that DHC12 is a mitochondrial-targeted neuroprotective iron-copper chelator and MAO-B inhibitor with potent antioxidant and mitochondria protective activities. Oral administration of low doses of DHC12 is a promising therapeutic strategy for the treatment of diseases with a mitochondrial iron accumulation component, such as PD.}, keywords = {activity, antioxidant antioxidant, basal brain chelator, complex content, coumarin-based coumarins, disease, ganglia, i, inhibitory-activity, iron iron-copper lipid-peroxidation, model, mouse neurodegeneration neurodegeneration, neuroprotection, niptp oxidative parkinsons stress, with}, pubstate = {published}, tppubtype = {article} } Disturbed iron homeostasis, often coupled to mitochondrial dysfunction, plays an important role in the progression of common neurodegenerative diseases such as Parkinson's disease (PD). Recent studies have underlined the relevance of iron chelation therapy for the treatment of these diseases. Here we describe the synthesis, chemical, and biological characterization of the multifunctional chelator 7,8-dihydroxy-4-((methylamino)methyl)-2H-chromen-2-one (DHC12). Metal selectivity of DHC12 was Cu2+ similar to Fe2+ > Zn2+ > Fe3+. No binding capacity was detected for Hg2+, co(2+), ca(2+), Mnz+, Mg2+, Ni2+, Pb2+ or Cd2+. DHC12 accessed cells colocalizing with Mitotracker Orange, an indication of mitochondrial targeting. In addition, DHC12 chelated mitochondrial and cytoplasmic labile iron. Upon mitochondrial complex I inhibition, DHC12 protected plasma membrane and mitochondria against lipid peroxidation, as detected by the reduced formation of 4-hydroxynonenal adducts and oxidation of C11-BODIPY581/891. DHC12 also blocked the decrease in mitochondrial membrane potential, detected by tetrarnethylrhodamine distribution. DHC12 inhibited MAO-A and MAO-B activity. Oral administration of DHC12 to mice (0.25 mg/kg body weight) protected substantia nigra pars compacta (SNpc) neurons against MPTP-induced death. Taken together, our results support the concept that DHC12 is a mitochondrial-targeted neuroprotective iron-copper chelator and MAO-B inhibitor with potent antioxidant and mitochondria protective activities. Oral administration of low doses of DHC12 is a promising therapeutic strategy for the treatment of diseases with a mitochondrial iron accumulation component, such as PD. |
2014 |
Labbe, C; Faini, F; Calderon, D; Molina, J; Arredondo, S Variations of Carnosic Acid and Carnosol Concentrations in Ethanol Extracts of Wild Lepechinia Salviae in Spring (2008-2011) Artículo de revista Natural Product Communications, 9 (10), pp. 1413-1416, 2014, ISSN: 1934-578x. Resumen | Enlaces | BibTeX | Etiquetas: antioxidant antioxidant, camosic camosol, cytotoxicity, dpph, lamiaceae, lepechinia rosemary, rosmarinus-officinalis, salvia @article{RN189, title = {Variations of Carnosic Acid and Carnosol Concentrations in Ethanol Extracts of Wild Lepechinia Salviae in Spring (2008-2011)}, author = { C. Labbe and F. Faini and D. Calderon and J. Molina and S. Arredondo}, url = {/brokenurl#<Go to ISI>://WOS:000343854800004}, issn = {1934-578x}, year = {2014}, date = {2014-01-01}, journal = {Natural Product Communications}, volume = {9}, number = {10}, pages = {1413-1416}, abstract = {Ethanol extracts from dried leaves of wild Lepechinia salvia (Lindl) Epling, collected during the flowering period (September-November), contained 15% to 25% camosic acid and 2 to 8% camosol, depending on the month of collection. The highest concentration of carnosic acid in extracts was in October, while camosol concentration had a peak in September, which suggests that it is not a product of camosic acid oxidation. A comparison of extracts obtained in September 2008 to 2011 shows that the production of both abietanes increased in years with less winter rainfall and higher temperatures, which induced an early blooming. ECsovalues in DPPH radical scavenging and antiproliferative (CCRF-CEM tumor cells) bioassays confirm that the high bioactivity of the extracts of rosemary, sage and L. salviae does not arise only from camosol and camosic acid. The cytotoxic activity was significantly higher in extracts of L. salviae, probably due to water stress differences between the cultivars and the wild species. These results correlate well with the close phylogenetic relationship between the three species, and their similar medicinal uses.}, keywords = {antioxidant antioxidant, camosic camosol, cytotoxicity, dpph, lamiaceae, lepechinia rosemary, rosmarinus-officinalis, salvia}, pubstate = {published}, tppubtype = {article} } Ethanol extracts from dried leaves of wild Lepechinia salvia (Lindl) Epling, collected during the flowering period (September-November), contained 15% to 25% camosic acid and 2 to 8% camosol, depending on the month of collection. The highest concentration of carnosic acid in extracts was in October, while camosol concentration had a peak in September, which suggests that it is not a product of camosic acid oxidation. A comparison of extracts obtained in September 2008 to 2011 shows that the production of both abietanes increased in years with less winter rainfall and higher temperatures, which induced an early blooming. ECsovalues in DPPH radical scavenging and antiproliferative (CCRF-CEM tumor cells) bioassays confirm that the high bioactivity of the extracts of rosemary, sage and L. salviae does not arise only from camosol and camosic acid. The cytotoxic activity was significantly higher in extracts of L. salviae, probably due to water stress differences between the cultivars and the wild species. These results correlate well with the close phylogenetic relationship between the three species, and their similar medicinal uses. |
2017 |
Neuroprotective Effect of a New 7,8-Dihydroxycoumarin-Based Fe2+/Cu2+ Chelator in Cell and Animal Models of Parkinson's Disease Artículo de revista Acs Chemical Neuroscience, 8 (1), pp. 178-185, 2017, ISSN: 1948-7193. |
2014 |
Variations of Carnosic Acid and Carnosol Concentrations in Ethanol Extracts of Wild Lepechinia Salviae in Spring (2008-2011) Artículo de revista Natural Product Communications, 9 (10), pp. 1413-1416, 2014, ISSN: 1934-578x. |